A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections.

Patrick J Kim Rafael Paolo Lansang Ronald B Vender

Published in: Journal of cutaneous medicine and surgery (2023)

The prevalence of injection site reaction in response to biologics ranges from 0.08 to 15.5%. Canakinumab, Dupilumab, Etanercept, and Ixekizumab had the highest prevalence of injection site reactions. Risankizumab, Brodalumab, Guselkumab, and Secukinumab had the lowest prevalence of injection site reactions. Recommendations are made regarding the improvement of adverse event reporting to better understand the epidemiology of injection site reactions.

Keyphrases

ultrasound guided
risk factors
rheumatoid arthritis
randomized controlled trial
emergency department
systematic review
clinical trial
systemic lupus erythematosus
clinical practice
rheumatoid arthritis patients
double blind